Long non-coding RNAs involved in cancer development and cell fate determination

Current Drug Targets

Volumn 13, Issue 13, 2012, Pages 1616-1621

  Kitagawa, Masatoshi ^a   Kotake, Yojiro ^b   Ohhata, Tatsuya ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KINKI UNIVERSITY   (Japan)

Author keywords

ANRIL; HOTAIR; Human cancers; INK4 locus; Kcnq1ot1; LncRNA; Polycomb; Xist

Indexed keywords

COMPLEMENTARY RNA; HOX ANTISENSE INTERGENIC RNA; LONG UNTRANSLATED RNA; POLYCOMB GROUP PROTEIN; UNCLASSIFIED DRUG; UNTRANSLATED RNA; UNTRANSLATED RNA ANRIL; UNTRANSLATED RNA KCNQ1OT1; UNTRANSLATED RNA MALAT1; UNTRANSLATED RNA NCRNACCND1; UNTRANSLATED RNA PANDA; X INACTIVE SPECIFIC TRANSCRIPT;

AGGRESSIVENESS; ARTICLE; CANCER PROGNOSIS; CANCER REGRESSION; CELL CYCLE; CELL FATE; GENE EXPRESSION; GENE LOCUS; GENETIC ASSOCIATION; HISTONE MODIFICATION; HUMAN; METASTASIS; NEOPLASM; ONCOGENE; PROTEIN METHYLATION; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL CYCLE; CELL DIFFERENTIATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; HUMANS; NEOPLASMS; RNA, LONG UNTRANSLATED;

EID: 84870159493     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012803530026     Document Type: Article

References (77)

1. Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 2008; 9: 219-230.
2. Sato F, Tsuchiya S, Meltzer SJ, Shimizu K. MicroRNAs and epigenetics. FEBS Journal 2011; 278: 1598-1609.
3. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4: 143-159. 6.
4. Carninci P, Kasukawa T, Katayama S, et al. FANTOM Consortium; RIKEN Genome Exploration Research Group and Genome Science Group (Genome Network Project Core Group). The transcriptional landscape of the mammalian genome. Science 2005; 309: 1559-1563.
5. Rinn JL, Kertesz M, Wang JK, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007; 129: 1311-1323.
6. Wang L, Brown JL, Cao R, Zhang Y, Kassis JA, Jones RS. Hierarchical recruitment of polycomb group silencing complexes. Mol Cell 2004; 14: 637-646.
7. Zhao J, Sun BK, Erwin JA, Song JJ, Lee JT. Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. Science 2008; 322: 750-756.
8. Nagano T, Mitchell JA, Sanz LA, et al. The Air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. Science 2008; 322: 1717-1720.
9. Saxena A, Carninci P. Long non-coding RNA modifies chromatin: epigenetic silencing by long non-coding RNAs. Bioessays 2011; 33: 830-839.
10. Hung T, Chang HY. Long noncoding RNA in genome regulation: prospects and mechanisms. RNA Biol 2010; 7: 582-585.
11. Kotake Y, Nakagawa T, Kitagawa K, et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene 2011; 30: 1956-1962.
12. Yap KL, Li S, Muñoz-Cabello AM, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 2010; 38: 662-674.
13. Gil J, Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 2006; 7: 667-677.
14. Kaneko S, Li G, Son J, et al. Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA. Genes Dev 2010; 24: 2615-2620.
15. Tsai MC, Manor O, Wan Y, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010; 329: 689-693.
16. Wan Y, Chang HY. HOTAIR: Flight of noncoding RNAs in cancer metastasis. Cell Cycle 2010; 9: 3391-3392.
17. Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464: 1071-1076.
18. Yang Z, Zhou L, Wu LM, et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol 2011; 18: 1243-1250.
19. Kogo R, Shimamura T, Mimori K, et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res 2011; 71: 6320-6326.
20. Niinuma T, Suzuki H, Nojima M, et al. Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Cancer Res 2012; 72: 1126-1136.
21. Kim K, Jutooru I, Chadalapaka G, et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene 2012. doi: 10.1038/onc.2012.193
22. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002; 2: 103-112.
23. Kitagawa K, Kotake Y, Kitagawa M. Ubiquitin-mediated control of oncogene and tumor suppressor gene products. Cancer Sci 2009; 100: 1374-1381.
24. Kotake Y, Cao R, Viatour P, Sage J, Zhang Y, Xiong Y. pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4a tumor suppressor gene. Genes Dev 2007; 21: 49-54.
25. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999; 397: 164-168.
26. Rayess H, Wang MB, Srivatsan ES. Cellular senescence and tumor suppressor gene p16. Int J Cancer 2012; 130:1715-1725.
27. Broadbent HM, Peden JF, Lorkowski S, et al. Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum Mol Genet 2008; 17: 806-814.
28. Holdt LM, Beutner F, Scholz M, et al. ANRIL expression is associated with atherosclerosis risk at chromosome 9p21. Arterioscler Thromb Vasc Biol 2010; 30: 620-627.
29. Cunnington MS, Santibanez Koref M, Mayosi BM, Burn J, Keavney B. Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ANRIL Expression. PLoS Genet 2010; 6: e1000899.
30. Pasmant E, Laurendeau I, Héron D, Vidaud M, Vidaud D, Bièche I. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res 2007; 67: 3963-3969.
31. Iacobucci I, Sazzini M, Garagnani P, et al. A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia. Leuk Res 2011; 35: 1052-1059.
32. Pasmant E, Sabbagh A, Masliah-Planchon J, et al.; NF France Network. Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1. J Natl Cancer Inst 2011; 103: 1713-1722.
33. Pandey RR, Mondal T, Mohammad F, et al. Kcnq1ot1 antisense noncoding RNA mediates lineage-specific transcriptional silencing through chromatin-level regulation. Mol Cell 2008; 32: 232-246.
34. Mager J, Montgomery ND, de Villena FP, Magnuson T. Genome imprinting regulated by the mouse Polycomb group protein Eed. Nat Genet 2003; 33: 502-507.
35. Umlauf D, Goto Y, Cao R, et al. Imprinting along the Kcnq1 domain on mouse chromosome 7 involves repressive histone methylation and recruitment of Polycomb group complexes. Nat Genet 2004; 36: 1296-1300.
36. Wagschal A, Sutherland HG, Woodfine K, et al. G9a histone methyltransferase contributes to imprinting in the mouse placenta. Mol Cell Biol 2008; 28: 1104-1113.
37. Arima T, Kamikihara T, Hayashida T, et al. ZAC, LIT1 (KCNQ1OT1) and p57KIP2 (CDKN1C) are in an imprinted gene network that may play a role in Beckwith-Wiedemann syndrome. Nucleic Acids Res. 2005; 33: 2650-2660.
38. Higashimoto K, Soejima H, Saito T, Okumura K, Mukai T. Imprinting disruption of the CDKN1C/KCNQ1OT1 domain: the molecular mechanisms causing Beckwith-Wiedemann syndrome and cancer. Cytogenet Genome Res 2006; 113: 306-312.
39. Nakano S, Murakami K, Meguro M, et al. Expression profile of LIT1/KCNQ1OT1 and epigenetic status at the KvDMR1 in colorectal cancers. Cancer Sci 2006; 97: 1147-1154.
40. Rodriguez BA, Weng YI, Liu TM, et al. Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cells. Carcinogenesis 2011; 32: 812-821.
41. Wijnen M, Alders M, Zwaan CM, Wagner A, van den Heuvel-Eibrink MM. KCNQ1OT1 hypomethylation: A Novel disguised genetic predisposition in sporadic pediatric adrenocortical tumors? Pediatr Blood Cancer 2011. doi: 10.1002/pbc.23398.
42. Wutz A. Gene silencing in X-chromosome inactivation: advances in understanding facultative heterochromatin formation. Nat Rev Genet 2011; 12: 542-553.
43. Wutz A, Rasmussen TP, Jaenisch R. Chromosomal silencing and localization are mediated by different domains of Xist RNA. Nat Genet 2002; 30: 167-174.
44. Duszczyk MM, Wutz A, Rybin V, Sattler M. The Xist RNA Arepeat comprises a novel AUCG tetraloop fold and a platform for multimerization. RNA 2011; 17: 1973-1982.
45. Maenner S, Blaud M, Fouillen L, et al. 2-D structure of the A region of Xist RNA and its implication for PRC2 association. PLoS Biol 2010; 8: e1000276.
46. Huynh KD, Lee JT. Inheritance of a pre-inactivated paternal X chromosome in early mouse embryos. Nature 2003; 426: 857-862.
47. Okamoto I, Otte AP, Allis CD, Reinberg D, Heard E. Epigenetic dynamics of imprinted X inactivation during early mouse development. Science 2004; 30: 644-649.
48. Mak W, Nesterova TB, de Napoles M, et al. Reactivation of the paternal X chromosome in early mouse embryos. Science 2004; 303: 666-669.
49. Barakat TS, Gribnau J. X chromosome inactivation in the cycle of life. Development 2012; 139: 2085-2089.
50. Stadtfeld M, Maherali N, Breault DT, Hochedlinger K. Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell 2008; 2: 230-240.
51. Marahrens Y, Panning B, Dausman J, Strauss W, Jaenisch R. Xistdeficient mice are defective in dosage compensation but not spermatogenesis. Genes Dev 1997; 11: 156-166.
52. Ohhata T, Senner CE, Hemberger M, Wutz A. Lineage-specific function of the noncoding Tsix RNA for Xist repression and Xi reactivation in mice. Genes Dev 2011; 25: 1702-1715.
53. Mugford JW, Yee D, Magnuson T. Failure of extra-embryonic progenitor maintenance in the absence of dosage compensation. Development 2012; 139: 2130-2138.
54. Agrelo R, Wutz A. ConteXt of change--X inactivation and disease. EMBO Mol Med 2010; 2: 6-15.
55. Weakley SM, Wang H, Yao Q, Chen C. Expression and function of a large non-coding RNA gene XIST in human cancer. World J Surg 2011; 35: 1751-1756.
56. Spatz A, Borg C, Feunteun J. X-chromosome genetics and human cancer. Nat Rev Cancer 2004; 4: 617-629.
57. Sirchia SM, Tabano S, Monti L, et al. Misbehaviour of XIST RNA in breast cancer cells. PLoS One 2009; 4: e5559.
58. Kawakami T, Zhang C, Taniguchi T, et al. Characterization of lossof- inactive X in Klinefelter syndrome and female-derived cancer cells. Oncogene 2004; 23: 6163-6169.
59. Benoît MH, Hudson TJ, Maire G, et al. Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines. Int J Oncol 2007; 30: 5-17.
60. Looijenga LH, Gillis AJ, van Gurp RJ, Verkerk AJ, Oosterhuis JW. X inactivation in human testicular tumors. XIST expression and androgen receptor methylation status. Am J Pathol 1997; 151: 581-590.
61. Kawakami T, Okamoto K, Ogawa O, Okada Y. XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer. Lancet 2004; 363: 40-42.
62. Song MA, Park JH, Jeong KS, Park DS, Kang MS, Lee S. Quantification of CpG methylation at the 5'-region of XIST by pyrosequencing from human serum. Electrophoresis 2007; 28: 2379-2384.
63. Hung T, Wang Y, Lin MF, et al. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet 2011; 43: 621-629.
64. Lin R, Roychowdhury-Saha M, Black C, et al. Control of RNA processing by a large non-coding RNA over-expressed in carcinomas. FEBS Lett 2011; 585: 671-676.
65. Xu C, Yang M, Tian J, Wang X, Li Z. MALAT-1: a long noncoding RNA and its important 3' end functional motif in colorectal cancer metastasis. Int J Oncol 2011; 39: 169-175.
66. Schmidt LH, Spieker T, Koschmieder S, et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol 2011; 6: 1984-1992.
67. Lin R, Maeda S, Liu C, Karin M, Edgington TS. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene 2007; 26: 851-858.
68. Wheeler TM, Leger AJ, Pandey SK, et al. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 2012; 488: 111-115.
69. Zhang B, Arun G, Mao YS, et al. The lncRNA Malat1 Is Dispensable for Mouse Development but Its Transcription Plays a cis-Regulatory Role in the Adult. Cell Rep 2012; 2: 111-123.
70. Eißmann M, Gutschner T, Hämmerle M, et al. Loss of the abundant nuclear non-coding RNA MALAT1 is compatible with life and development. RNA Biol 2012; 9(8). [Epub ahead of print].
71. Schmidt LH, Spieker T, Koschmieder S, et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol 2011; 6: 1984-1992.
72. Wilusz JE, Freier SM, Spector DL. 3' end processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA. Cell 2008; 135: 919-932.
73. Miyagawa R, Tano K, Mizuno R, et al. Identification of cis- and trans-acting factors involved in the localization of MALAT-1 noncoding RNA to nuclear speckles. RNA 2012; 18: 738-751.
74. Wang X, Arai S, Song X, et al. Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature 2008; 454: 126-130.
75. Haile S, Lal A, Myung JK, Sadar MD. FUS/TLS is a co-activator of androgen receptor in prostate cancer cells. PLoS One 2011; 6: e24197.
76. Kurokawa R. Promoter-associated long noncoding RNAs repress transcription through a RNA binding protein TLS. Adv Exp Med Biol 2011; 722: 196-208.
77. Oyoshi T, Kurokawa R. Structure of noncoding RNA is a determinant of function of RNA binding proteins in transcriptional regulation. Cell Biosci 2012; 2: 1.